Isoxsuprine Hydrochloride

Isoxsuprine HCI occurs as a white odorless, crystalline powder, having a bitter
taste, It has a following structural formula

Each tablet contains lsoxsuprine HCI 20 mg.

These tablets contain the following inactive ingredients: dibasic calcium phosphate (anhydrous), lactose, magnesium stearate. microcrystalline cellulose, povidone k30, and sodium starch glycolate.

Oral
There are no known contraindications to oral use when administered in recommended doses. Should not be given immediately postpartum or in the presence of arterial bleeding.

On rare occasion, oral administration of the drug has been associated in time with the occurrences of hypotension, tachycardia, chest pain, nausea, vomiting, dizziness, abdominal distress, and severe rash.  If rash appears, the drug should be discontinued.

Although available evidence suggests a temporal association of these reactions with isoxsuprine, a casual relationship can be neither confirmed nor refuted.

β-Adrenergic receptor stimulants such as Isoxsuprine Hydrochloride have been used to inhibit pre-term labor. Maternal and fetal tachycardia may occur under such use. Hypocalcemia, hypoglycemia, hypotension and ileus have been reported to occur in infants whose mothers received isoxsuprine. Pulmonary edema has been reported in mothers treated with β-stimulants. Isoxsuprine HCl tablets, USP is neither approved nor recommended for use in the treatment of premature labor.

Isoxsuprine HCI tablets, USP are supplied in HDPE bottles.

20 mg Bottles of 1,000's: NDC61971-065-10

Manufactured in India by
Vista Pharmaceuticals, Limited.

For
Vista Pharmaceuticals, Inc.
Revised:07/2017